Addressing needs in oncology and infectious diseases through data-driven innovation


Learn more about Globavir’s recent news items


Globavir's Oncology pipeline includes preclinical candidates targeting HIF - 1α/p300 and IDO/TDO

Both are expected to enter clinical trials in 2017

Infectious Diseases

Globavir's Infectious Disease pipeline includes GBV006, a broad spectrum antiviral being evaluated for the treatment of Ebola and Dengue infections

Globavir also offers best-in-class Dengue Diagnostic tests